巴瑞替尼治疗重度斑秃的头发生长轨迹分析
基于BRAVE-AA1和BRAVE-AA2两项III期试验,通过生长混合模型将巴瑞替尼治疗的重度斑秃患者分为早期、逐渐和晚期应答亚组,各亚组比例因剂量而异,且受基线疾病特征影响。
要点
- 巴瑞替尼4mg组早期、逐渐、晚期应答者及无应答者比例分别为33%、28%、8%和31%。
- 巴瑞替尼2mg组早期、逐渐、晚期应答者及无应答者比例分别为20%、23%、9%和49%。
- 早期应答者更常见于基线重度而非极重度斑秃患者,且应答者更常见于脱发病程短于4年者。
核心结论
- 巴瑞替尼治疗重度斑秃患者可识别出早期、逐渐和晚期应答亚组,这些亚组受基线特征影响,有助于设定头发生长的治疗预期。
研究设计与样本
- BRAVE-AA1和BRAVE-AA2两项III期试验纳入重度斑秃患者(SALT评分≥50),随机分配至巴瑞替尼4mg或2mg每日一次治疗52周,基于生长混合模型按首次达到SALT30的时间分类应答亚组。
主要发现
- 巴瑞替尼4mg组和2mg组分别有69%和51%的患者在第52周前至少一次达到SALT30。
- 巴瑞替尼4mg组早期、逐渐、晚期应答者及无应答者比例分别为33%、28%、8%和31%;2mg组分别为20%、23%、9%和49%。
- 早期应答者较逐渐或晚期应答者更快达到最大临床结局,例如第36周时超过78%的早期应答者达到SALT评分≤20。
- 早期应答者在基线重度斑秃(SALT评分50至<95)患者中比极重度斑秃(SALT评分95-100)患者中更常见。
- 总体而言,应答者(早期至晚期)在脱发病程短(<4年)的患者中更常见。
关键数值与推荐
- SALT30定义为SALT评分较基线改善≥30%。
- 早期应答:第12周内达到SALT30;逐渐应答:第12周后至第36周达到SALT30;晚期应答:第36周后至第52周达到SALT30。
临床怎么用
- 这些分析结果有助于为巴瑞替尼治疗重度斑秃患者的头发生长预期提供参考。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. OBJECTIVES: To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. METHODS: The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]. Patients randomized to baricitinib 4 mg or 2 mg retained their treatment allocation for 52 weeks. Based on patterns identified through growth mixture modelling (GMM), patients were categorized into responder subgroups according to when they first achieved ≥ 30% improvement from baseline in SALT score (SALT30). For each responder subgroup, trajectories of response (i.e. achievement of a SALT score ≤ 20, SALT score ≤ 10 and ≥ 50% change from baseline in SALT score) and baseline disease characteristics are reported. RESULTS: Respectively, 515 and 340 patients were randomized to once-daily baricitinib 4 mg and 2 mg at baseline; 69% and 51%, respectively, achieved SALT30 at least once by week 52. Based on GMM findings, we identified three responder subgroups: early (SALT30 by week 12), gradual (SALT30 after week 12-week 36) and late (SALT30 after week 36-week 52). The proportions of early, gradual and late responders and nonresponders were, respectively, 33%, 28%, 8% and 31% among patients treated with baricitinib 4 mg, and 20%, 23%, 9% and 49%, respectively, among those treated with baricitinib 2 mg. Early responders had a shorter trajectory to maximal clinical outcomes (e.g. > 78% achieved a SALT score ≤ 20 by week 36) vs. gradual or late responders. Early responders were more frequent among patients with baseline severe AA (SALT score 50 to < 95) vs. very severe AA (SALT score 95-100). Overall, responders (early to late) were more frequent in patients with short (< 4 years) episodes of hair loss. CONCLUSIONS: These analyses identified early, gradual and late responder subgroups for scalp hair regrowth in baricitinib-treated patients with severe AA, and that these subgroups are influenced by baseline characteristics. Findings from these analyses will help to inform treatment expectations for scalp hair regrowth.
引用
- King B, Shapiro J, Ohyama M, et al. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. Br J Dermatol. 2023. PMID: 37708254. doi:10.1093/bjd/ljad253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。